Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2026 07:00 ET | Source: Seres Therapeutics, Inc.

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live...
May 05, 2026 07:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Dupixent showed significant and clinically meaningful improvements in both esophageal distensibility as well as disease-related structural changes and inflammation in the esophagus in adult patients...
May 05, 2026 04:00 ET | Source: Oculis Holding AG

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

ZUG, Switzerland, May 05, 2026 (GLOBE NEWSWIRE) -- Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular...
May 05, 2026 04:00 ET | Source: Oculis Holding AG

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) managementOculis is on track to report...
May 05, 2026 03:05 ET | Source: 4Bio Capital

4BIO Capital leads oversubscribed £61 million ($83m) Series A financing of Cytospire Therapeutics

4BIO Capital joined by new investors Servier Ventures, Sound Bioventures, British Business Bank and Criteria Bio Ventures, supported by existing investors Abingworth and LifeArc VenturesCytospire’s...
May 05, 2026 03:00 ET | Source: Cytospire

Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer

Series A financing led by 4BIO Capital, with major new investors Servier Ventures, Sound Bioventures, British Business Bank and Criteria Bio Ventures, supported by existing investors Abingworth and...
May 04, 2026 16:30 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first quarter...
May 04, 2026 16:01 ET | Source: Hemab Therapeutics, Inc.

Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that...
May 04, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight

New York, USA, May 04, 2026 (GLOBE NEWSWIRE) -- Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight The...
May 04, 2026 08:00 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...